Eli Lilly and Company $LLY Shares Purchased by Modera Wealth Management LLC

Key Points

• Modera Wealth Management increased its Eli Lilly position by 6.5% in the third quarter, purchasing 2,976 additional shares for a total holding of 48,573 shares valued at approximately $56.2 million.
• Institutional investors own 82.53% of LLY’s shares, with BlackRock, State Street and Bank of America among the largest holders. Meanwhile, insiders sold 13,500 shares worth about $16.0 million over the past three months under pre-arranged trading plans.
• Eli Lilly reported strong quarterly results, with revenue up 38.6% to $24.4 billion and adjusted EPS of $7.48, prompting the company to raise its 2026 revenue forecast. Analysts maintain a broadly bullish outlook, with a consensus “Moderate Buy” rating and a $1,398.43 price target, though elevated valuation and pricing pressure remain risks.

Modera Wealth Management LLC lifted its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 6.5% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 48,573 shares of the company's stock after purchasing an additional 2,976 shares during the period. Modera Wealth Management LLC's holdings in Eli Lilly and Company were worth $56,202,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently made changes to their positions in LLY. BlackRock Inc. boosted its position in Eli Lilly and Company by 1.6% during the 2nd quarter. BlackRock Inc. now owns 67,540,400 shares of the company's stock valued at $81,009,981,000 after buying an additional 1,046,558 shares during the period. State Street Corp raised its stake in shares of Eli Lilly and Company by 1.7% during the second quarter. State Street Corp now owns 36,215,754 shares of the company's stock valued at $43,438,262,000 after acquiring an additional 605,752 shares during the last quarter. Bank of America Corp DE bought a new position in shares of Eli Lilly and Company during the second quarter valued at about $13,522,666,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Eli Lilly and Company by 1.9% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,209,385 shares of the company's stock worth $8,647,153,000 after purchasing an additional 137,364 shares during the period. Finally, Jennison Associates LLC boosted its holdings in shares of Eli Lilly and Company by 7.9% during the second quarter. Jennison Associates LLC now owns 5,461,416 shares of the company's stock worth $6,550,587,000 after purchasing an additional 400,538 shares during the period. Institutional investors own 82.53% of the company's stock.

Insider Transactions at Eli Lilly and Company

In other news, EVP Patrik Jonsson sold 6,500 shares of the stock in a transaction on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the sale, the executive vice president directly owned 54,147 shares of the company's stock, valued at approximately $63,628,139.70. This represents a 10.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the firm's stock in a transaction on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the transaction, the executive vice president owned 11,875 shares of the company's stock, valued at $14,131,250. The trade was a 29.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 13,500 shares of company stock valued at $15,958,170. Insiders own 0.14% of the company's stock.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Q3 results substantially beat expectations. Revenue rose 39% year over year to $24.4 billion, while adjusted EPS was $7.48 versus the $5.68 consensus estimate. Mounjaro sales increased 65% to $10.7 billion and Zepbound sales rose 49% to $5.35 billion. Lilly third-quarter results
• Positive Sentiment: Lilly raised its 2026 revenue forecast to $91 billion-$92 billion, up from $85 billion-$87 billion previously. Strong demand, broader Medicare access and growing middle-income adoption are supporting expectations for continued GLP-1 expansion. Q3 earnings call highlights
• Positive Sentiment: Analysts raised their price targets and maintained bullish ratings. Scotiabank lifted its target to $1,605 with a “sector outperform” rating, Morgan Stanley raised its target to $1,596 with an “overweight” rating, and RBC moved to $1,600 with an “outperform” rating. Analyst commentary
• Positive Sentiment: Pipeline and portfolio diversification offer additional upside. Positive Phase 3 retatrutide data strengthened Lilly’s competitive position against Novo Nordisk, while oncology, immunology and neuroscience products are beginning to contribute more meaningfully. Lilly growth opportunities
• Negative Sentiment: Investors face execution and valuation risks. Realized prices fell 15%, meaning volume growth must continue to offset pricing pressure. Results also benefited from roughly $900 million in one-time items, and acquired in-process research charges weighed on earnings. With GLP-1 drugs representing a large share of revenue and the stock near its high, expectations are elevated. Reuters earnings report

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on LLY shares. Wells Fargo & Company boosted their price target on Eli Lilly and Company from $1,330.00 to $1,500.00 and gave the company an "overweight" rating in a report on Friday. UBS Group reiterated a "buy" rating and issued a $1,625.00 price objective on shares of Eli Lilly and Company in a report on Friday. Guggenheim lifted their price objective on Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the stock a "buy" rating in a research report on Friday, September 18th. TD Cowen reiterated a "buy" rating and issued a $1,250.00 price objective on shares of Eli Lilly and Company in a research report on Tuesday, September 22nd. Finally, Bank of America reissued a "buy" rating and set a $1,497.00 target price on shares of Eli Lilly and Company in a research note on Friday. One research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company currently has an average rating of "Moderate Buy" and a consensus price target of $1,398.43.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $1,415.64 on Monday. The company has a quick ratio of 1.00, a current ratio of 1.39 and a debt-to-equity ratio of 1.17. The business's 50 day moving average price is $1,197.72 and its 200-day moving average price is $1,092.57. Eli Lilly and Company has a 52 week low of $834.19 and a 52 week high of $1,449.68. The stock has a market cap of $1.33 trillion, a P/E ratio of 45.95, a P/E/G ratio of 1.80 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The company reported $7.48 earnings per share for the quarter, topping the consensus estimate of $5.71 by $1.77. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The company had revenue of $24.40 billion for the quarter, compared to the consensus estimate of $22.58 billion. During the same quarter in the prior year, the business posted $7.02 EPS. The firm's quarterly revenue was up 38.6% compared to the same quarter last year. Equities research analysts anticipate that Eli Lilly and Company will post 35.18 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend is Friday, November 13th. Eli Lilly and Company's payout ratio is 22.46%.

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company's portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer's disease.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.